Aptevo Therapeutics (APVO) Leases (2019 - 2025)
Aptevo Therapeutics' Leases history spans 7 years, with the latest figure at $4.0 million for Q3 2025.
- For Q3 2025, Leases fell 12.32% year-over-year to $4.0 million; the TTM value through Sep 2025 reached $4.0 million, down 12.32%, while the annual FY2024 figure was $4.4 million, 10.08% down from the prior year.
- Leases for Q3 2025 was $4.0 million at Aptevo Therapeutics, down from $4.1 million in the prior quarter.
- Across five years, Leases topped out at $5.5 million in Q2 2022 and bottomed at $1.3 million in Q1 2022.
- The 5-year median for Leases is $4.5 million (2024), against an average of $4.0 million.
- The largest annual shift saw Leases crashed 46.58% in 2022 before it surged 298.16% in 2023.
- A 5-year view of Leases shows it stood at $1.6 million in 2021, then surged by 234.79% to $5.3 million in 2022, then decreased by 7.96% to $4.9 million in 2023, then dropped by 10.08% to $4.4 million in 2024, then dropped by 9.71% to $4.0 million in 2025.
- Per Business Quant, the three most recent readings for APVO's Leases are $4.0 million (Q3 2025), $4.1 million (Q2 2025), and $4.3 million (Q1 2025).